94.25 USD
↗ 0.65 (0.69%)LIVE (AS OF 12:40 PM EDT)
Spyre Therapeutics, Inc. Common Stock
SYRENASDAQ • USD
Market: OPEN
Shares of Spyre Therapeutics, Inc. Common Stock (SYRE) are trading at $94.25. The technical outlook is "Sell" and the fundamental picture shows "Neutral". Notable factors include a robust Altman Z-Score, a weak Piotroski F-Score of 0/9, negative Return on Equity and a bullish Golden Cross on the moving averages. Valuation metrics place SYRE at a fair price relative to peers.
Technical & fundamental data as of Aug 26, 2026.
Open?$93.61
High?$95.25
Low?$91.87
Prev. Close?$93.61
Volume?555.4K
Avg. Volume?926.9K
VWAP?$93.51
Rel. Volume?0.60x
Bid / Ask
Bid?$80.65 × 100
Ask?$94.13 × 100
Spread?$13.48
Midpoint?$87.39
Valuation & Ratios
Market Cap?8.3B
Shares Out?87.9M
Float?75.4M
Float %?86.8%
P/E Ratio?N/A
P/B Ratio?7.50
EPS?-$1.70
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
Spyre Therapeutics Inc is a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of care for inflammatory bowel disease (IBD) and rheumatic diseases. Spyre's pipeline includes extended half-life antibodies targeting α4β7, TL1A, and IL-23 in development as monotherapies and pair-wise combinations. It has a single reportable segment, which is the development of biopharmaceutical products for the treatment of patients with IBD and other immune-mediated disease.
Address
221 CRESCENT STREET
WALTHAM, MA 02453
Phone: (617) 651-5940
WALTHAM, MA 02453
Phone: (617) 651-5940
Technical OutlookSell
Strong SellNeutralStrong Buy
Long-Term (Tide)?– Neutral(0/3)
Medium-Term (Wave)?▼ Bearish(-3/3)
Short-Term (Ripple)?▼ Bearish(-3/3)
MA Alignment?Mixed
Full Technical Analysis →Fundamental OutlookNeutral
Strong SellNeutralStrong Buy
F-Score?3
Z-Score?100
Momentum?50
Short Sent.?39
Piotroski F-Score?0/9Weak
Altman Z-Score?67.82Safe
Confidence?52%Low
Short InterestVery High
Short % of Float?15.60%High
Short Interest?11.8M
Days to Cover?16.0
Free Float75.4M
Avg Daily Volume736.8K
Settlement Date2026-08-14
Financial Health
Current Ratio?18.53Strong
Quick Ratio?18.53Strong
Cash Ratio?2.56Strong
Debt/Equity?0.00Low
ValuationATTRACTIVELY VALUEDvs 1 peers + S&P 500
Score83/100
P/E?N/A▾
P/B?7.50FAIR▾
Peers100
S&P25
P/S?N/A▾
P/FCF?N/A▾
EV/EBITDA?-29.8CHEAP▾
S&P97
EV/Sales?N/A▾
Returns & Efficiency
ROE?-13.6%WEAK▾
S&P9
ROA?-12.8%WEAK▾
S&P3
Cash Flow & Enterprise
FCF?$-208944000
Enterprise Value?$8.1B
Fundamentals ratios updated end of day